**Conflict of interest**

The authors declare no conflict of interest, financial or otherwise.

#### **Funding**

This work was supported by RFBR (project 20-015-00102).

dose of 4 mg/kg, an increase of the reaction thresholds induced by GZK-111 was observed after 90 min (F(4, 44) = 3.8743, p = 0.00881) that persisted for up to 2 h (F(4, 44) = 3.2141, p = 0.02124), compared with the control group (p < 0.05 and p < 0.05, respectively) (**Figure 7**). The data obtained indicate that GZK-111

*The effect of GZK-111 on immobilization time in the Porsolt forced swimming test in mice after 14-day*

*\*<sup>р</sup> <sup>&</sup>lt; 0.05, the statistical significance of the differences relative to control group by the unpaired t-Student criterion; #*

exhibits dose-dependent analgesic activity, like CPG in rats [40].

**Experimental groups**

*Experiment 1*

*Experiment 2*

*n, number of animals;*

*n, number of animals;*

*administration, compared to CPG.*

*p < 0.05;*

**Table 5.**

**266**

**Table 4.**

*administration.*

**Dose, mg/kg, i.p. (n = 10)**

*Neuroprotection - New Approaches and Prospects*

*Notes: Immobilization time was taken as 100% for control animals.*

**(n = 10)**

*Notes: Immobilization time was taken as 100% for control animals.*

**Compound Dose, mg/kg, i.p.**

Control 0.0 235.8 11.8 100 GZK-111 0.1 240.2 19.8 101 GZK-111 0.5 235.3 17.7 100 GZK-111 1.0 240.0 22.1 101 GZK-111 5.0 253.9 9.2 108 Amitriptyline 10.0 218.5 17.9\* 93

Control 275.3 8.7 100 GZK-111 0.01 260.1 7.3 94 GZK-111 5.0 268.7 10.2 98 GZK-111 10.0 245.5 9.1\* 89 GZK-111 20.0 259.9 9.2 94

*\*р < 0.05, the statistical significance of the differences relative to control group by the unpaired t-Student criterion.*

**Immobilization time, s**

0.1 188.4 9.3 105 1.0 163.2 11.2 (p = 0.08) 91 10.0 157.7 9.2\* 88

(p = 0.06)

1.0 <sup>97</sup> <sup>6</sup># <sup>70</sup> 2.0 <sup>101</sup> 8# <sup>73</sup>

*The effect of GZK-111 on immobilization time in the Porsolt forced swimming test in mice after 7-day*

GZK-111 Control 180.1 10.7 100

10.0 (p.o.) 160.3 10.4

CPG [9] Control 139 8 100

Fluoxetine [9] 10.0 <sup>87</sup> 9# <sup>63</sup>

**Immobilization time, s**

**Immobilization time compared to the control, %**

**Immobilization time compared to the control, %**

89

*Neuroprotection - New Approaches and Prospects*

## **Author details**

Ksenia N. Koliasnikova<sup>1</sup> , Polina Yu. Povarnina<sup>1</sup> , Anna V. Tallerova<sup>1</sup> , Yulia N. Firsova<sup>1</sup> , Sergei V. Nikolaev<sup>2</sup> , Tatiana A. Antipova<sup>2</sup> , Anna V. Nadorova<sup>3</sup> , Larisa G. Kolik3 , Tatiana A. Gudasheva<sup>1</sup> \* and Sergei B. Seredenin<sup>2</sup>

**References**

10.1007/BF00772132

[2] Gudasheva TA, Boyko SS, Akparov VK, Ostrovskaya RU, Skoldinov SP, Rozantsev GG, et al. Identification of a novel endogenous

memory facilitating cyclic dipeptide cyclo-prolylglycine in rat brain. FEBS Letters. 1996;**391**:

Trofimov SS, Voronina TA, Skoldinov AP, Seredenin SB. New endogenous dipeptide cycloprolylglycine is similar to piracetam by its mnemotropic selectivity. Bulletin of Experimental Biology and Medicine.

1999;**128**(4):1012-1014

1017928116025

1016293904149

**269**

[3] Gudasheva TA, Ostrovskaya RU,

[4] Gudasheva TA, Konstantinopol'skii MA, Ostrovskaya RU, Seredenin SB. Anxiolytic activity of endogenous nootropic dipeptide cycloprolylglycine in elevated plus-maze test. Bulletin of Experimental Biology and Medicine. 2001;**131**(5):464-466. DOI: 10.1023/a:

[5] Seredenin SB, Gudasheva TA, Boiko SS, Kovalev GI, Voronin MV, Yarkova MA. Endogenous dipeptide cycloprolylglycine shows selective anxiolytic activity in animals with manifest fear reaction. Bulletin of Experimental Biology and Medicine. 2002;**133**(4):360-362. DOI: 10.1023/a:

[6] Kolyasnikova KN, Gudasheva TA,

Voronina TA, Seredenin SB. Similarity of cycloprolylglycine to piracetam in antihypoxic and neuroprotective effects. Eksperimental'naia i

Nazarova GA, Antipova TA,

149-152

[1] Gudasheva TA, Vasilevich NI, Zolotov NN, Lezina VP, Rozenberg SG, Kravchenko EV, et al. Nootropic action of proline-based topological analogs of piracetam. Pharmaceutical Chemistry Journal. 1991;**25**(6):363-367. DOI:

*Glyproline Pro-Ampakine with Neuroprotective Activity DOI: http://dx.doi.org/10.5772/intechopen.91192*

Klinicheskaia Farmakologiia. 2012;

[7] Povarnina PY, Kolyasnikova KN,

neuroprotective activity after systemic administration to rats with modeled incomplete global ischemia and in vitro modeled glutamate neurotoxicity. Bulletin of Experimental Biology and Medicine. 2016;**160**(5):653-655. DOI:

[8] Ferro JN, de Aquino FL, de Brito RG, Dos Santos PL, Quintans Jde S, de Souza LC, et al. Cyclo-Gly-Pro, a cyclic dipeptide, attenuates nociceptive behavior and inflammatory response in mice. Clinical and Experimental Pharmacology and Physiology. 2015;**42**(12):1287-1295.

Nikolaev SV, Antipova TA, Gudasheva TA. Neuropeptide cycloprolylglycine exhibits

10.1007/s10517-016-3241-5

DOI: 10.1111/1440-1681.12480

[9] Kovalev GI, Abdullina AA, Vasil'eva EV, Gudasheva TA, Seredenin SB. Antidepressant-like properties of cycloprolylglycine. Eksperimental'naia i Klinicheskaia Farmakologiia. 2018;**81**(11):3-6. (in Russ). DOI: 10.30906/0869-2092-2018-81-11-3-6

[10] Garibova TL, Gudasheva TA, Seredenin SB. A new component in the

[11] Gudasheva TA, Grigoriev VV, Koliasnikova KN, Zamoyski VL, Seredenin SB. Neuropeptide cycloprolylglycine is an endogenous positive modulator of AMPA receptors. Doklady Biochemistry

10.1134/S160767291606003X

Antipova TA, Seredenin SB.

and Biophysics. 2016;**471**(1):387-389. DOI:

[12] Gudasheva TA, Koliasnikova KN,

mechanism of regulation of endogenous depressive-like states. Doklady Biochemistry and Biophysics. 2019;**488**(1):324-326. DOI: 10.1134/

S1607672919050107

**75**(9):3-6. (in Russ)

1 Department of Medicinal Chemistry, V.V. Zakusov Research Institute of Pharmacology, Russia

2 Department of Pharmacogenetics, V.V. Zakusov Research Institute of Pharmacology, Russia

3 Laboratory of Pharmacological Regulation of Alcohol and Drug Dependence, V.V. Zakusov Research Institute of Pharmacology, Russia

\*Address all correspondence to: tata-sosnovka@mail.ru

© 2020 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/ by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

*Glyproline Pro-Ampakine with Neuroprotective Activity DOI: http://dx.doi.org/10.5772/intechopen.91192*
